© The Canadian Journal of Urology™; 19(Supplement 1); October 2012
References
1.
Izawa JI, Klotz L, Siemens DR et al. Prostate cancer screening:
Canadian guidelines 2011. The CanadianUrologicalAssociation.
Can Urol Assoc J
2011;5(4):235-240.
2.
Yin M, Bastacky S, Chandran U et al. Prevelance of incidental
prostate cancer in the general population: a study of healthy
organ donors.
J Urol
2008;179(3):892-895.
3.
Getzenberg RH, Wein AJ. Prostate Cancer Tumor Markers.
Campbell-WalshUrology 10
th
Ed. WeinAJ, Kavoussi LR, Novick
AC, PartinAW, Peters CA. NewYork: Saunders 2010;2748-2762.
4.
Cooperberg MR, Lubeck DP, Mehta SS et al. Time trends in
clinical risk stratification for prostate cancer: implications for
outcomes.
J Urol
2003;170(6
Pt 2):S21-S25.
5.
Moyer VA. Screening for prostate cancer: U.S. Preventive
Services Task Force recommendation statement.
Ann InternMed
2012;157(2):120-134.
6.
Schroder FH, Hugosson J, Roobol MJ et al. Screening and
prostate-cancer mortality in a randomized European study.
N Engl J Med
2009;360(13):1320-1328.
7.
Andriole GL, Crawford D, Grubb RL, et al. Mortality results
from a randomized prostate-cancer screening trial.
N Engl J Med
2009;360(13):1310-1319.
8.
Eckersberger E, Finkelstein J, Sadri H et al. Screening for
prostate cancer: a reviewof the ERSPC and PLCO trials.
Rev Urol
2009;11(3):127-133.
9.
Schroder FH, Hugosson J, Roobol MJ et al. Prostate cancer
mortality at 11 years of follow up.
N Engl J Med
2012;366(11):
981-990.
10.
Hugosson J, Carlsson S, Aus G et al. Mortality results from the
Göteborg randomisedpopulation-basedprostate-cancer screening
trial.
Lancet Oncol
2010;11(8):725-732.
11.
Carter HB, Ferrucci L, Kettermann A et al. Detection of life-
threatening prostate cancerwith prostate specific antigen velocity
cut points in prostate cancer screening.
J Urol
2007; 177:499.
12.
GreenKL,Whitson JM, Carroll PR. Prostate cancer earlydetection
using serum prostate specific antigen.
AUAUpdates Series
2011;
30:82-87.
13.
Thompson IM, Chi C,Ankerst DPet al. Effect of finasteride on the
sensitivity of PSAfor detecting prostate cancer.
J Natl Cancer Inst
2006;98(16):1128-1133.
14.
Thompson IM, Goodman PJ, Tangen TM et al. The influence of
finasteride on the development of prostate cancer.
N Engl J Med
2003;349(3):215-224.
15.
AndrioleGL,BostwickDG,BrawleyOWetal.Effectofdutasteride
on the risk of prostate cancer.
N Engl J Med
2010;362(13):
1192-1202.
16.
Roobol MJ, Steyerberg EW, Kranse R et al. Arisk-based strategy
improves prostate-specific antigen-driven detection of prostate
cancer.
Eur Urol
2010;57(1):79-85.
17.
Herman MP, Dorsey P, John M et al. Techniques and predictive
models to improve prostate cancer detection.
Cancer
2009;115
(13
Suppl):3085-3099.
18.
Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing
risk analysis of men aged 55 to 74 years at diagnosis managed
conservatively for clinically localizedprostate cancer.
JAMA
1998;
280(11):975-980.
19.
Catalona WJ, Han M. Definitive Therapy for Localized Prostate
Cancer. Campbell-Walsh Urology 10
th
Ed. Wein AJ, Kavoussi LR,
Novick AC, Partin AW, Peters CA. New York: Saunders 2010;
2771-2778.
20.
Madersbacher S, Marberger M. High-energy shockwaves and
extracorporeal high-intensity focused ultrasound.
J Endourol
2003;17(8):667-672.
21.
LiuXS, FoliaC, Gomella LG. Pharmacology for common urologic
diseases: 2011 review for the primary care physician.
Can J Urol
2011;18(
Suppl 1):24-38.
22.
Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on
prostate cancer. Part 1: screening, diagnosis, and treatment of
clinically localised disease.
Eur Urol
2011;59(1):61-71.
23.
Saad F, Hotte SJ. Guidelines for the management of castrate-
resistant prostate cancer.
Can Urol Assoc J
2010;4(6):380-384.
24.
Sanofi-Aventis Canada Inc. Jevtana (cabazitaxel for injection)
product monograph. June 20, 2012.
25.
Janssen Inc. Zytiga (abiraterone acetate tablets) product
monograph. Toronto, ON; Sept 11, 2012.
26.
de Bono JS, Logothetis CJ, Molina A et al; COU-AA-301
Investigators. Abiraterone and increased survival in metastatic
prostate cancer.
N Engl J Med
2011;364(21):1995-2005.
27.
35
PSA implications and medical management of prostate cancer for the primary care physician
